178 related articles for article (PubMed ID: 16397047)
1. p8 is a new target of gemcitabine in pancreatic cancer cells.
Giroux V; Malicet C; Barthet M; Gironella M; Archange C; Dagorn JC; Vasseur S; Iovanna JL
Clin Cancer Res; 2006 Jan; 12(1):235-41. PubMed ID: 16397047
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
[TBL] [Abstract][Full Text] [Related]
4. Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Chen Z; Zhao L; Shi K; Chen B
Clin Lab; 2018 May; 64(5):749-757. PubMed ID: 29739052
[TBL] [Abstract][Full Text] [Related]
5. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Yao J; Qian C
Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
[TBL] [Abstract][Full Text] [Related]
7. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
8. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
9. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Ina S; Hirono S; Noda T; Yamaue H
Pancreas; 2010 May; 39(4):473-85. PubMed ID: 19959962
[TBL] [Abstract][Full Text] [Related]
10. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Tan J; Zhou X; Zhu H
Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
[TBL] [Abstract][Full Text] [Related]
11. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Zhong ZQ; Song MM; He Y; Cheng S; Yuan HS
Asian Pac J Cancer Prev; 2012; 13(8):3781-9. PubMed ID: 23098471
[TBL] [Abstract][Full Text] [Related]
13. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
14. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Huanwen W; Zhiyong L; Xiaohua S; Xinyu R; Kai W; Tonghua L
Mol Cancer; 2009 Dec; 8():125. PubMed ID: 20021699
[TBL] [Abstract][Full Text] [Related]
16. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
[TBL] [Abstract][Full Text] [Related]
17. The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.
An N; Cheng D
Pathol Oncol Res; 2020 Jan; 26(1):425-431. PubMed ID: 30406400
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
[TBL] [Abstract][Full Text] [Related]
19. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Jiang C; Yi XP; Shen H; Li YX
World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]